Adverse drug reactions · people with familial Mediterranean fever
It is very uncertain whether colchicine (oral) changes adverse drug reactions compared with placebo (very low certainty).
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of attacksa · children with familial Mediterranean fever
1 finding from 1 review
Time between attacks · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of AA amyloidosis · children with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · children with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · children with familial Mediterranean fever
1 finding from 1 review
Intervention not reported
Recurrent pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower recurrent pericarditis Chest pain + (ECG changes +/‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic… (moderate certainty).
1 finding from 1 review
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review